B.Riley Financial Maintains Buy Rating on Hyperfine with $1.40 Price Target

B.Riley Financial reaffirms its Buy rating on Hyperfine (HYPR) with a $1.40 price target. Analyst Yuan Zhi, who has a 4-star rating and 40.22% success rate, maintains a Buy rating on the stock. Hyperfine has an analyst consensus of Moderate Buy and a price target consensus of $1.27, implying a -1.55% downside from current levels.

Title: Hyperfine (HYPR) Q2 2025 Earnings: Analysts Reaffirm Buy Rating

Hyperfine Inc. (NASDAQ: HYPR) is set to release its Q2 2025 earnings on August 13, 2025. Analysts expect the company to report a loss of ($0.12) per share and revenue of $3.00 million for the quarter [1]. The company's last earnings report, released on May 13, 2025, saw a negative net margin of 343.42% and a negative return on equity of 74.19%, with revenue of $2.14 million [1].

B. Riley Financial has reaffirmed its Buy rating on Hyperfine with a $1.40 price target. Analyst Yuan Zhi, who has a 4-star rating and 40.22% success rate, maintains a Buy rating on the stock [2]. The analyst consensus remains Moderate Buy with a price target consensus of $1.27, implying a -1.55% downside from current levels [2].

Hyperfine's Q2 2025 results are anticipated to show a 26% sequential revenue growth, driven by the sale of its next-gen MRI system priced at $550,000 with a 15% premium over the prior version [2]. Gross margin expanded to 49.3%, reflecting AI-enhanced imaging and pricing discipline, with projections exceeding 50% as production scales [2]. The company has also expanded into international markets, including Canada, Australia, and New Zealand, and office-based neurology, targeting underserved segments with portable MRI solutions [2].

Hyperfine's Swoop® system, the only FDA-cleared ultra-low-field portable MRI with AI, offers unique value in resource-limited settings and clinical validation for Alzheimer’s diagnostics [2]. The company's commercial strategy includes expanding into office-based neurology practices and international markets, with plans to launch in Europe by the end of 2025 [2].

While Hyperfine remains a high-growth, high-margin play in AI-driven healthcare innovation, it still operates at a net loss. However, its declining cash burn and cash reserves of $25.4 million provide a runway through 2026 [2]. The company's execution in 2025, coupled with a $6.2 billion market opportunity, makes it a compelling long-term play for investors seeking exposure to the intersection of AI and medical innovation [2].

References
[1] https://www.marketbeat.com/instant-alerts/hyperfine-hypr-to-release-quarterly-earnings-on-wednesday-2025-08-06/
[2] https://www.ainvest.com/news/hyperfine-hypr-2025-inflection-point-gen-ai-powered-mri-technology-2508/